Full Text Journal Articles from
Abstract 29164151

Advertisement

Find full text journal articles








Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.

PMID: 29164151 (view PubMed database entry)
DOI: 10.1155/2017/9849823 (read at publisher's website )
PMCID: PMC5661091 (free full text version available)

Download PDF Download PDF

Zhanyi Li, Ying Liu, Ying Zhang, Xiaoqiong Shao, Qiumin Luo, Xiaoyan Guo, Guoli Lin, Qingxian Cai, Zhixin Zhao, Yutian Chong,

<h4>Background and objective</h4>The direct-acting antiviral agents (DAAs) antiviral therapy has drastically improved the prognosis of hepatitis C virus (HCV) patients. However, the viral drug resistance-associated variants (RAVs) can limit the efficacy of DAAs. For the HCV-6a is not the predominant prevalent genotype; the data on the prevalence of naturally occurring RAVs in it is scarce. Our study aims to assess the prevalence of RAVs in treatment-naive HCV-6a patients.<h4>Methods</h4>Nested PCR assays were performed on 95 HCV-6a patients to amplify HCV viral regions of NS3, NS5A, and NS5B.<h4>Results</h4>In NS3/4A region, we detected Q80K in 95.5% isolates (84/88) and D168E in 2.3% isolates (2/88). In NS5A region, we detected Q30R in 93.2% isolates (82/88), L31M in 4.6% isolates (4/88), and H58P in 6.8% isolates (6/88). In NS5B region, we detected A15G in 2.3% isolates (2/88), S96T in 1.1% isolates (1/88), and S282T in 20.7% isolates (17/88) and we detected I482L in 100% isolates (4/4), V494A in 50% isolates (2/4), and V499A in 100% isolates (4/4).<h4>Conclusions</h4>RAVs to DAAs preexist in treatment-naive HCV-6a patients. Further studies should address the issue of the impact of RAVs in response to DAA therapies for HCV-6a patients.

Biomed Res Int (BioMed research international)
[2017, 2017:9849823]

Cited: 5 times

AltMetric Statistics




Advertisement

Disclaimer
0.4446 s